BioCentury
ARTICLE | Clinical News

MEDI starts Phase II psoriasis study

September 17, 2001 7:00 AM UTC

MedImmune (MEDI) began dosing patients in the U.S. and Canada in a double-blind, placebo-controlled Phase II study of siplizumab (MEDI-507) to treat psoriasis. The study will measure safety, efficacy,...